The record → All 107 providers → Hims
Provider record
Is Hims legit?
Yes — Hims is a real, operating US telehealth company, not a fake storefront. That is usually what the question means, and it is the easy part.
The harder part is what it sells you. It supplies FDA-approved medication only. We have 4 sourced regulatory or legal actions on record against it, listed below with links to the primary documents.
Visit Hims →Plain link, no affiliate arrangement — Hims does not pay us.
What it actually supplies
Supplies FDA-approved medication only — Wegovy, Zepbound, Ozempic, Mounjaro or the approved oral versions. Higher priced, and outside the compounding enforcement entirely.
Named on its own site: Wegovy Pill, Wegovy Pen, Zepbound Vial, Zepbound KwikPen, Ozempic, Ozempic Pill, Mounjaro, Foundayo (orforglipron).
What regulators and courts have said
Each of these links to its source, and each says which kind of source that is. We publish what the record says and nothing beyond it — an action against a company is not proof that a particular customer was harmed.
September 2025
FDA warning letter to Hims & Hers Health, Inc. dba Hims (MARCS-CMS 716567) over compounded GLP-1 marketing.
March 2026
Novo Nordisk sued Hims & Hers for infringement of US Patent 8,129,343 in the District of Delaware on 9 February 2026 (No. 1:26-cv-00143) and voluntarily dismissed it without prejudice on 9 March 2026, expressly reserving the right to refile, under an agreement in which Hims & Hers stopped advertising compounded GLP-1s and began distributing Novo's FDA-approved semaglutide.
July 2026
The FTC, the State of Utah and Los Angeles County sued Hims & Hers Health, Inc. in the Northern District of California under FTC Act section 5 and ROSCA, alleging the company disclosed customers' health information to advertising platforms including Meta and Snap, charged consumers before the promised provider consultation, and obstructed cancellation; allegations unproven.
June 2025
Consolidated securities class action, In re Hims & Hers Health, Inc. Securities Litigation, No. 25-cv-05315 (N.D. Cal.), first filed 25 June 2025, alleging misrepresentations about the company's business and its Novo Nordisk relationship; disclosed by the company in its Form 10-Q for the quarter ended 30 June 2026. Allegations unproven.
Other signals on file
Not regulatory or legal actions, and not counted as any. These are recorded because they are sourced and worth knowing — complaint volumes, third-party reports, disputes between companies.
June 2025
Novo Nordisk terminated its collaboration with Hims & Hers, alleging illegal sham compounding and Chinese-sourced unapproved API.
Worth knowing
Hims was the flagship compounded-semaglutide seller but is branded-only as of the 9 March 2026 Novo Nordisk settlement; third-party content describing Hims as a compounder is out of date. Medication prices run $149/mo (Wegovy Pill) to $1,899/mo (Mounjaro, Zepbound) on top of the membership.
Go direct
The link below is a plain link to Hims and earns us nothing. Hims has no affiliate arrangement with this site, and is recorded here on exactly the same terms as the companies that do pay.
Visit Hims →Cheaper on paper
Providers with a lower advertised starting price. Check what each one supplies before comparing — the number alone does not tell you what arrives.
Head to head
Compared with the alternatives
Side-by-side records for the companies people weigh Hims against.
$149 vs $74 a month
Compare the records →Hims vs Hers$149 vs $149 a month
Compare the records →Hims vs Noom (Noom Med)$149 vs $179 a month
Compare the records →Hims vs Calibrate$149 vs $199 a month
Compare the records →Hims vs Henry Meds$149 vs $179 a month
Compare the records →Hims vs LillyDirect$149 vs $299 a month
Compare the records →Straight answers
Hims, in short
- Is Hims legit?
- Hims is a real, operating US telehealth company, not a fake storefront. It supplies FDA-approved medication only. We have 4 sourced regulatory or legal actions on record against it: FDA warning letter to Hims & Hers Health, Inc. dba Hims (MARCS-CMS 716567) over compounded GLP-1 marketing; Novo Nordisk sued Hims & Hers for infringement of US Patent 8,129,343 in the District of Delaware on 9 February 2026 (No. 1:26-cv-00143) and voluntarily dismissed it without prejudice on 9 March 2026, expressly reserving the right to refile, under an agreement in which Hims & Hers stopped advertising compounded GLP-1s and began distributing Novo's FDA-approved semaglutide; The FTC, the State of Utah and Los Angeles County sued Hims & Hers Health, Inc. in the Northern District of California under FTC Act section 5 and ROSCA, alleging the company disclosed customers' health information to advertising platforms including Meta and Snap, charged consumers before the promised provider consultation, and obstructed cancellation; allegations unproven; Consolidated securities class action, In re Hims & Hers Health, Inc. Securities Litigation, No. 25-cv-05315 (N.D. Cal.), first filed 25 June 2025, alleging misrepresentations about the company's business and its Novo Nordisk relationship; disclosed by the company in its Form 10-Q for the quarter ended 30 June 2026. Allegations unproven.
- Does Hims sell compounded or FDA-approved medication?
- FDA-approved medication only. Supplies FDA-approved medication only — Wegovy, Zepbound, Ozempic, Mounjaro or the approved oral versions. Higher priced, and outside the compounding enforcement entirely.
- How much does Hims cost?
- From $149 a month, with medication billed separately. A promotional first month is advertised at $39.